Extended Spectrum-Lactamases among Gram-Negative Bacterial Isolates from Clinical Specimens in Three Major Hospitals in Northern Jordan
Open Access
- 1 January 2009
- journal article
- research article
- Published by Wiley in International Journal of Microbiology
- Vol. 2009, 1-8
Abstract
Background and Objectives. Extended spectrum-lactamase (ESBL) production is increasing all over the world, and organisms other thanE. coliandK. pneumoniaeare acquiring this character. ESBL production is detectable by automation, E-test, double disk diffusion (DDD), and PCR. This study aimed to determine the prevalence of ESBL production among clinical isolates of gram-negative rods, and to evaluate the effectiveness of augmentation of clavunate with Cefotaxime, Ceftazoxime, Aztreonam, Ceftriaxone, and Cefpodoxime in detecting ESBL production.Methods. 472 clinical gram-negative isolates identified by standard methods were tested for ESBL-production by (DDD) method using six cephalosporins and amoxicillin-clavulinate discs.Results. 108/472 (22.9%) of the isolates were ESBL producers, and were prevalent in tertiary care hospitals. 88.2% ofE. cloacae, 71.4% ofK. pneumoniae, 28.6% ofK. oxytoca, 12.5% ofC. freundii, 11.1% ofA. calcoacceticus, and 10.8% ofE. coliwere ESBL producers. The DDD test demonstrated some variations in the efficacy of the different cephalosporins in detecting all the ESBL producers. The inclusion of ceftizoxime discs increased the efficacy of the test. It is concluded that ESBL-producing bacteria were prevalent among our hospitalized patients, and involved genera other thanKlebsiellaandEscherichia, and the inclusion of ceftizoxime increased the efficacy of ESBL detection by the DDD test.
Keywords
Funding Information
- Jordan University of Science and Technology
This publication has 32 references indexed in Scilit:
- Extended-Spectrum Beta-Lactamase Detection with Different Panels for Automated Susceptibility Testing and with a Chromogenic MediumJournal of Clinical Microbiology, 2008
- Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in KoreaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- A Novel Class A Extended-Spectrum β-Lactamase (BES-1) in Serratia marcescens Isolated in BrazilAntimicrobial Agents and Chemotherapy, 2000
- A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates ofKlebsiella pneumoniaeandEscherichia coliin JapanFEMS Microbiology Letters, 2000
- High incidence of Klebsiella pneumoniae clinical isolates to extended-spectrum B-lactam drugs in intensive care unitsDiagnostic Microbiology and Infectious Disease, 2000
- Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamasesFEMS Microbiology Letters, 1997
- Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamasesFEMS Microbiology Letters, 1997
- Molecular characterisation by PCR-restriction fragment length polymorphism of TEM β-lactamasesFEMS Microbiology Letters, 1995
- Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable β-lactamases (TEM, SHV, CARB)FEMS Microbiology Letters, 1991